Loading clinical trials...
Loading clinical trials...
A Phase 1 Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 Monotherapy and Combination Therapy in Adult Participants With Hepatic Impairment
Conditions
Interventions
VIR-2218
VIR-3434
Locations
5
United States
Inland Empire Clinical Trials
Rialto, California, United States
Orange County Research Center
Tustin, California, United States
CenExel Research Centers of America
Hollywood, Florida, United States
Floridian Clinical Research
Miami Lakes, Florida, United States
Texas Liver Institute
San Antonio, Texas, United States
Start Date
September 21, 2022
Primary Completion Date
September 25, 2026
Completion Date
April 30, 2027
Last Updated
June 13, 2025
NCT07439939
NCT05597488
NCT06680583
NCT07471542
NCT07469319
NCT07324616
Lead Sponsor
Vir Biotechnology, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions